← back to search

Min Li

Fujian University of Traditional Chinese Medicine · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include RNA modifications and cancer, Cancer-related molecular mechanisms research, Cancer, Hypoxia, and Metabolism, and Cancer Research and Treatments.
h-index
53
citations
10,277
works
520
NIH funding
primary concept
Medicine
email

Recent publications

Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia
Cancer Cell 2026cited by 2position: contributordoi
Cancer cachexia: A tumor-driven disorder of whole-body homeostasis.
2026cited by 0position: contributordoi
Why immunotherapy fails in immune-cold tumors: A systems framework from immune baseline to designable immune remodeling.
2026cited by 0position: contributordoi
Unraveling stress-adaptation pathways in cancer: Functional dissection through CRISPR-based genetic screens.
2026cited by 0position: contributordoi
Stress dynamically modulates neuronal autophagy to gate depression onset
Nature 2025cited by 40position: middledoi
A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity
Proceedings of the National Academy of Sciences 2025cited by 8position: lastdoi
Regulated cell death in cancer: Mechanisms, crosstalk, and opportunities for therapy.
2025cited by 7position: contributordoi
A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.
2025cited by 7position: contributordoi
ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16.
2025cited by 6position: contributordoi
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.
2025cited by 3position: contributordoi
Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.
2025cited by 3position: contributordoi
Tumor microenvironment and macroenvironment: A new perspective on holistic oncology.
2025cited by 2position: contributordoi
Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy.
2025cited by 2position: contributordoi
Publisher Correction: Stress dynamically modulates neuronal autophagy to gate depression onset
Nature 2025cited by 1position: middledoi
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy.
2025cited by 1position: contributordoi
Synergy between photonics and biological approaches-A review of combination therapies for cancer theranostics.
2025cited by 1position: contributordoi
Author Correction: Stress dynamically modulates neuronal autophagy to gate depression onset
Nature 2025cited by 0position: middledoi
Glutaminase 2-Mediated Yes Associated Protein 1 Glutamylation Facilitates Immune Evasion in Pancreatic Ductal Adenocarcinoma.
2025cited by 0position: contributordoi
A novel mechanism of the cachexia-promoting action of chemotherapy drugs fluorouracil and cisplatin
2025cited by 0position: contributordoi
Supplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Supplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Supplementary Fig. S4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Supplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Data from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Supplementary Table S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Supplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi
Supplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 38 papers (2020–2026)Jingxuan Yang · University of Hong Kong26 papers (2014–2025)Courtney W. Houchen · Centre For Digestive Diseases22 papers (2021–2025) · 16 papers (2020–2025)Michael S. Bronze · OU Health15 papers (2024–2025)Wei R. Chen · Shandong University15 papers (2024–2025) · 15 papers (2021–2025)Yuqing Zhang · Chinese Academy of Medical Sciences & Peking Union Medical College14 papers (2025–2025) · 14 papers (2025–2025) · 14 papers (2025–2025)Yu Ren · Chongqing University14 papers (2023–2025)Hao Yuan · University of Oklahoma Health Sciences Center14 papers (2025–2025)Kuirong Jiang · Sun Yat-sen University14 papers (2025–2025) · 13 papers (2025–2025)Mingyang Liu · Elsevier, Inc.13 papers (2025–2025) · 13 papers (2025–2025) · 13 papers (2025–2025)Alex X. Arreola · Oklahoma State University13 papers (2025–2025)Sophia W. Zhao · 13 papers (2025–2025)Qun Chen · Jiangsu Province Hospital13 papers (2025–2025)